CRESCENT BIOPHARMA, INC. Earnings Per Share (Diluted)
CRESCENT BIOPHARMA, INC. (CBIO) reported Earnings Per Share (Diluted) of -$0.59 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2025-05-14
- CRESCENT BIOPHARMA, INC. earnings per share, diluted for the quarter ending 2024-12-31 was -$0.28.
- CRESCENT BIOPHARMA, INC. earnings per share, diluted for the quarter ending 2024-09-30 was -$0.15.
- CRESCENT BIOPHARMA, INC. earnings per share, diluted for the quarter ending 2024-06-30 was -$0.16.
- CRESCENT BIOPHARMA, INC. earnings per share, diluted for the quarter ending 2024-03-31 was -$0.04.
- CRESCENT BIOPHARMA, INC. earnings per share, diluted for fiscal 2024 was -$0.59.
- CRESCENT BIOPHARMA, INC. earnings per share, diluted for fiscal 2023 was -$0.58.
- CRESCENT BIOPHARMA, INC. earnings per share, diluted for fiscal 2022 was -$0.89.
- CRESCENT BIOPHARMA, INC. earnings per share, diluted for fiscal 2021 was -$1.23.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 3 month as first filed | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | -$0.28 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.59 10-K · filed 2025-02-13 | |||
| 2024-09-30 | -$0.15 10-Q · filed 2024-11-13 | -$0.48 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | -$0.16 10-Q · filed 2024-08-08 | -$0.32 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | -$0.04 10-Q · filed 2025-05-14 | -$0.17 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | -$0.58 10-K · filed 2025-02-13 | ||||
| 2023-09-30 | -$0.14 10-Q · filed 2024-11-13 | -$0.44 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | -$0.13 10-Q · filed 2024-08-08 | -$0.30 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | -$0.17 10-Q · filed 2025-05-14 | ||||
| 2022-12-31 | -$0.89 10-K · filed 2024-03-27 | ||||
| 2022-09-30 | -$0.16 10-Q · filed 2023-11-03 | -$0.70 10-Q · filed 2023-11-03 | |||
| 2022-06-30 | -$0.25 10-Q · filed 2023-08-02 | -$0.53 10-Q · filed 2023-08-02 | |||
| 2022-03-31 | -$0.28 10-Q · filed 2023-05-03 | ||||
| 2021-12-31 | -$1.23 10-K · filed 2024-03-27 | ||||
| 2021-09-30 | -$0.34 10-Q · filed 2022-11-09 | -$0.90 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | -$0.28 10-Q · filed 2022-08-03 | -$0.56 10-Q · filed 2022-08-03 | |||
| 2021-03-31 | -$0.28 10-Q · filed 2022-04-28 | ||||
| 2020-12-31 | -$1.12 10-K · filed 2023-03-29 | ||||
| 2019-12-31 | -$1.34 10-K · filed 2022-03-03 | ||||
| 2016-06-30 | -$0.41 10-Q · filed 2016-08-04 | -$0.80 10-Q · filed 2016-08-04 | |||
| 2015-12-31 | -$0.47 10-K · filed 2017-03-01 | ||||
| 2015-09-30 | -$0.38 10-K · filed 2017-03-01 | -$0.20 10-Q · filed 2015-11-12 | |||
| 2015-06-30 | $0.51 10-K · filed 2017-03-01 | $0.16 10-Q · filed 2016-08-04 | |||
| 2015-03-31 | -$0.37 10-K · filed 2017-03-01 | ||||
| 2014-12-31 | -$0.39 10-K · filed 2016-02-29 | -$0.60 10-K · filed 2015-03-16 | |||
| 2014-09-30 | -$0.35 10-K · filed 2016-02-29 | -$0.20 10-Q · filed 2015-11-12 | |||
| 2014-06-30 | $0.39 10-K · filed 2016-02-29 | $0.15 10-Q · filed 2015-08-06 | |||
| 2014-03-31 | -$0.30 10-K · filed 2016-02-29 | ||||
| 2013-12-31 | -$2.80 10-K · filed 2015-03-16 | -$8.87 10-K · filed 2015-03-16 | |||
| 2013-09-30 | -$3.00 10-K · filed 2015-03-16 | ||||
| 2013-06-30 | -$3.70 10-K · filed 2015-03-16 | -$3.24 10-Q · filed 2014-07-31 | |||
| 2013-03-31 | $0.04 10-K · filed 2015-03-16 | ||||
| 2012-12-31 | $0.33 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |